Windtree Therapeutics ( (WINT) ) has released a notification of late filing.
Windtree Therapeutics, Inc. has filed a Form 12b-25, notifying a delay in their Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the company’s limited resources, which have been stretched due to efforts in seeking capital through potential strategic transactions. This has diverted attention from finalizing their financial statements and disclosures. Windtree Therapeutics anticipates filing the delayed report on or before April 15, 2025, within the extension period allowed. The company does not expect any significant changes in financial results from the previous year. Windtree Therapeutics is committed to compliance, as indicated by the signature of Jamie McAndrew, Senior Vice President, Chief Financial Officer, and Corporate Secretary.
More about Windtree Therapeutics
YTD Price Performance: -91.07%
Average Trading Volume: 2,925,208
Technical Sentiment Signal: Buy
Current Market Cap: $1.09M
For a thorough assessment of WINT stock, go to TipRanks’ Stock Analysis page.